Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibodutant - Menarini Pharmaceuticals

Next Previous
X
Search
Drug Profile

Ibodutant - Menarini Pharmaceuticals

Alternative Names: MEN-15596

Latest Information Update: 02 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Menarini
  • Class Small molecules; Thiophenes
  • Mechanism of Action Neurokinin 2 receptor antagonists; Tachykinin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 02 Feb 2018 Discontinued - Phase-II for Irritable bowel syndrome in Ukraine (PO)
  • 02 Feb 2018 Discontinued - Phase-III for Irritable bowel syndrome in Hungary, Latvia, Sweden, Spain, Slovakia, Germany, United Kingdom, Poland, Singapore, Bulgaria, France, Italy, USA, Russia, Romania, Czech Republic (PO)
  • 31 May 2016 Menarini terminates its phase III trial for Irritable bowel syndrome in USA, Hungary, Latvia, Sweden, Slovakia, Germany and United Kingdom prior to May 2016(NCT02120027) (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top